I remember DM doing a presentation with a slide that showed other development stage drugs and the valuations they achieved when they were in phase 2 or 3.....and then its compared to Resverlogix and Apabetalone and there's this big disconnect.  The other drugs, the valuations assigned soared into the billions if memory serves...while we can't even get to 1/2 a billion CDN. 

Maybe someone remembers the presentation(s) I'm referring to and can post the link.  

But regardless of the lofty valuations those drugs received...they all ultimately failed, so while I'm sure investors were excited and thinking things boded well based on climbing share prices....it didn't help them achieve clinical success.

Maybe we shouldn't be so worried about a lofty PPS here?  Let the science prove itself and the valuation will follow.  Better to start low and end up high than the other way around.